On 18 December 2006, orphan designation (EU/3/06/422) was granted by the European Commission to Oasmia Pharmaceutical AB, Sweden, for paclitaxel (micellar) for the treatment of ovarian cancer.

Key facts

Active substance
Paclitaxel (micellar)
Disease / condition
Treatment of ovarian cancer
Date of first decision
EU designation number

Review of designation

The Committee for Orphan Medicinal Products reviewed the orphan designation of Apealea at the time of marketing authorisation.

The sponsor formally requested the withdrawal of the orphan designation prior to the Committee’s final opinion. More information is available in the PDF iconwithdrawal assessment_report - orphan maintenance.

Sponsor's contact details

Oasmia Pharmaceutical AB
Vallongatan 1
SE 753 17 Uppsala
Tel. + 46 1850 5440
Fax + 46 1851 0873

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;

How useful was this page?

Add your rating